Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NoxopharmASX:NOX -3.16% 3-Year EBITDA Growth Rate is 38.00% as of Dec. 2025, which is 25% above its 10-year median of 30.35. The stock has 4 warning signs investors should review. Among 1,129 Biotechnology companies, Noxopharm ranks better than 76.62% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 38.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Noxopharm was 44.40% per year. The lowest was 9.90% per year. And the median was 30.35% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Noxopharm 3-Year EBITDA Growth Rate Related Terms
ASX:NOX vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Noxopharm's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Noxopharm 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Noxopharm's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Noxopharm's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 38.00% mean?
Noxopharm (ASX:NOX) has a 3-Year EBITDA Growth Rate of 38.00% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Noxopharm and its competitors. This is 25% above median its historical median of 30.35. Over the past decade, Noxopharm's 3-Year EBITDA Growth Rate has ranged from 9.90 to 44.40. According to the industry distribution chart, Noxopharm ranks #264 out of 1129 companies in the Biotechnology industry, placing it in the top 23.4%.
Is Noxopharm's 3-Year EBITDA Growth Rate too high?
Noxopharm's current 3-Year EBITDA Growth Rate of 38.00% is 25% above median its 10-year median of 30.35. Over the past 10 years, this metric has ranged from a low of 9.90 to a high of 44.40. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Noxopharm's value of 38.00% is 155% above this industry median. Based on the distribution chart, Noxopharm ranks #264 out of 1129 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Noxopharm's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Noxopharm ranks #264 out of 1129 companies for 3-Year EBITDA Growth Rate. This places Noxopharm in the top 23% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. Noxopharm's value of 38.00% is 155% above this benchmark. Historically, Noxopharm's own 3-Year EBITDA Growth Rate has ranged from 9.90 to 44.40 over the past decade. While the company's 10-year median is 30.35 vs. the industry median of 14.90, Noxopharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,129 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Noxopharm's current 3-Year EBITDA Growth Rate of 38.00% is 155% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Noxopharm and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Noxopharm's current 3-Year EBITDA Growth Rate is 38.00%, which is 25% above median its own 10-year median of 30.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noxopharm stock overvalued right now?
Noxopharm (ASX:NOX) has a current 3-Year EBITDA Growth Rate of 38.00%. The current 3-Year EBITDA Growth Rate is 38.00%, which is 25% above median its 10-year median of 30.35 and 155% above the Biotechnology industry median of 14.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Noxopharm (ASX:NOX), the current 3-Year EBITDA Growth Rate is 38.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Noxopharm Ltd is an Australian clinical-stage drug development company focused on discovering and developing novel treatments for cancer and inflammation, as well as improving mRNA vaccines, based on two preclinical platforms. It is engaged in one segment which is the clinical development in the field of both oncology and non-oncology in the pan-pacific region.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:NOX has been successfully added to your 
